415 related articles for article (PubMed ID: 20350661)
21. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
22. Treatment of splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
[TBL] [Abstract][Full Text] [Related]
23. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in high-grade lymphoma.
Zwick C; Murawski N; Pfreundschuh M;
Semin Hematol; 2010 Apr; 47(2):148-55. PubMed ID: 20350662
[TBL] [Abstract][Full Text] [Related]
25. [Splenic marginal zone lymphoma associated with antiphospholipid antibodies].
Yokoi T; Mori S; Sugimoto H; Komiyama Y; Uemura Y; Tanijiri R; Nakai K; Matsumoto N; Zen K; Amakawa R; Kishimoto Y; Ieko M; Takahashi H; Fukuhara S
Rinsho Ketsueki; 2004 Oct; 45(10):1095-9. PubMed ID: 15553043
[TBL] [Abstract][Full Text] [Related]
26. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
Orciuolo E; Buda G; Sordi E; Baraté C; Galimberti S; Ciancia E; Petrini M
Leuk Res; 2010 Feb; 34(2):184-9. PubMed ID: 19414190
[TBL] [Abstract][Full Text] [Related]
27. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
28. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Bennett M; Yegena S; Dave HP; Schechter GP
Hematol Oncol; 2008 Jun; 26(2):114. PubMed ID: 18271062
[No Abstract] [Full Text] [Related]
29. Rituximab monotherapy for splenic marginal zone lymphoma.
Bennett M; Sharma K; Yegena S; Gavish I; Dave HP; Schechter GP
Haematologica; 2005 Jun; 90(6):856-8. PubMed ID: 15951303
[TBL] [Abstract][Full Text] [Related]
30. [Splenic marginal zone B-cell lymphoma with bilateral renal invasion after splenectomy].
Hoshino T; Iriuchijima H; Ogawa Y; Irisawa H; Jinbo T
Rinsho Ketsueki; 2008 Jan; 49(1):35-9. PubMed ID: 18277594
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
32. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
34. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
35. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
36. Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.
Harada S; Kalla H; Balasubramanian M; Brodsky I; Gladstone D; Hou JS
Ann Diagn Pathol; 2008 Jun; 12(3):212-6. PubMed ID: 18486899
[TBL] [Abstract][Full Text] [Related]
37. [Successful treatment of splenic lymphoma with villous lymphocytes by rituximab and laparoscopic splenectomy].
Fujita T; Asagoe K; Sakoda H
Rinsho Ketsueki; 2003 Apr; 44(4):249-53. PubMed ID: 12784658
[TBL] [Abstract][Full Text] [Related]
38. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
40. Splenic marginal zone lymphoma.
Oscier D; Owen R; Johnson S
Blood Rev; 2005 Jan; 19(1):39-51. PubMed ID: 15572216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]